10
Feb
2021
18:00
GMT
Webinar
New Insights With Real-Time, Remote Cardiac Monitoring: Learnings From the Pivotal TEASE-Study
-
Views:
1231
-
Likes:
3
Overview
The pandemic is creating a paradigm shift in remote patient care. Join us for an interactive and educational webinar presenting first-hand results of the TEASE-study, where novel patient-empowered technology was used to remotely monitor stroke patients’ hearts in everyday life.
The results of the TEASE-study are pivotal: by monitoring with the Coala Heart Monitor, it was possible to detect previously undiagnosed AF in 9% of cryptogenic stroke patients at a mean of 19.7 days post stroke – non-invasively, patch-free and at very high patient satisfaction.
The webinar will also discuss how non-invasive, patient-empowered monitors can used as alternative to ECG patches and as complementary to insertable cardiac monitors (ICM). Real-time cardiac monitoring offer abilities of early and immediate drug treatment.
Faculty:

Peter Magnusson
Philip Siberg
This webinar is supported by

Agenda
Audience
- This webinar aims to engage physicians, nurses, and managers with an interest in remote monitoring in general and arrhythmias in particular with a special attention to cryptogenic stroke.
Learning Objectives
- Opportunities and benefits in monitoring patients in real-time from home.
- The role of Coala Heart Monitor in remote monitoring, stroke management and patient compliance in diverse populations.
- Organization of care and handling of large volume ECG tracings - present and future perspectives.
- Tailored evaluation and treatment - when to use real-time ECG in relation to other diagnostic tools.
Faculty Biographies

Peter Magnusson
Peter Magnusson, MD, PhD received his medical degree from Lund University and the PhD from Karolinska Institute.
Philip Siberg
Philip is an international serial entrepreneur, CEO and Board Member within the medical technology and life science tech sectors. Philip co-founded Coala Life in 2015 and has led several ventures to global expansion and 2x IPOs on Nasdaq.